Corbyn M Gilmore

Mr. Corbyn M Gilmore

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
BGBretton Alex Gilmore
Bretton Alex Gilmore
CGCorbyn M Gilmore
Corbyn M Gilmore
KRKelly R Reveles
Kelly R Reveles
JKJim M. Koeller
Jim M. Koeller
JSJodi H. Spoor
Jodi H. Spoor
Christopher Raymond FreiChristopher Raymond Frei
Christopher Raymond Frei
Despite efforts to dissuade major manufacturers and retailers from marketing and selling vape products to adolescents, the practice of vaping continues to increase in this population. Few studies have assessed adolescent perceptions of vaping, access to vaping, and use of vaping, and most rely, at least in part, on inferential conclusions drawn from data on smoking traditional combustible cigarettes. A novel electronic survey was created to assess the use of vapes, perceptions of vaping, and access to vaping among a convenience sample of adolescents (ages 12–20 years) in eleven schools in South-Central Texas from May to August 2021. The students’ perceived threat of negative health outcomes due to vaping was calculated based on questions soliciting perceptions of severity (perceived danger) and susceptibility (perceived likelihood of illness). Trends were identified using descriptive and bivariate statistical tests. A total of 267 respondents were included; 26% had tried vaping. A majority (63%) did not believe vaping and smoking were synonymous. Most (70%) thought it was easy to obtain supplies and (76%) vape before and after (88%) or even during (64%) school. Respondents who vaped had a 34% lower perceived threat when compared to respondents who did not vape. In this sample of adolescents from South-Central Texas, one in four reported that they had tried vaping. Easy access to vapes and misperceptions regarding the safety of vaping might create a false sense of security with respect to vaping as an alternative to smoking, particularly among those who reported vaping, and is likely contributing to the increased use of vapes.

19 September 2025 in Rheumatology and Therapy
Verified
Journal Article
Open access
PDF file
AVAdriana Vargus
Adriana Vargus
CGCorbyn M Gilmore
Corbyn M Gilmore
JKJim M. Koeller
Jim M. Koeller
Grace LeeGrace Lee
Grace Lee
HPHaridarshan Patel
Haridarshan Patel
Christopher Raymond FreiChristopher Raymond Frei
Christopher Raymond Frei
Introduction Gout is an inflammatory arthritis that, when uncontrolled, can lead to chronic pain, disability, increased demand for healthcare, and poor health outcomes. This study sought to identify patients with gout and to describe the differences in epidemiology, pharmacotherapy, healthcare utilization, and outcomes for patients with controlled and uncontrolled gout in the United States (US) Veterans Affairs (VA) healthcare system. Methods This retrospective cohort study used electronic health record (EHR) data from VA patients from all US states and territories with gout from 1/1/2016 to 12/31/2022. The study included adult VA patients (18 +) with a diagnosis code for gout (ICD10 codes M10 or M1A) and two or more encounters 30 or more days apart. Uncontrolled gout was defined as one serum uric acid level (sUA) level > 8 mg/dl, tophi, or both in the study period. Results Of the 331,664 patients who met study criteria, 42% (138,068) were considered to have uncontrolled gout and 58% (193,596) were controlled. The uncontrolled group was younger (mean age 64 vs. 70 years, p < 0.01), and both groups were predominantly white non-Hispanic (58% and 70%) and male (99% and 99%). Specialist visits were more common in the uncontrolled group during follow-up: podiatry (38% vs. 30%, p < 0.01), rheumatology (24% vs. 9%, p < 0.01), and nephrology (24% vs. 12%, p < 0.01). Patients with uncontrolled gout were also significantly more likely to be seen in the emergency room (55% vs. 38%, p < 0.01) or admitted to the hospital (47% vs. 37%, p < 0.01) during follow-up. Conclusions Nearly half of VA patients with gout met criteria for uncontrolled gout, and these patients experienced greater healthcare utilization and worse health outcomes than patients with controlled gout. Patients with uncontrolled gout could benefit from additional/alternative approaches such as the adoption of a treat-to-target strategy and increasing referrals to a specialist.

2 September 2025 in Journal of Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
CGCorbyn M Gilmore
Corbyn M Gilmore
AVAdriana Vargus
Adriana Vargus
GLGrace C. Lee
Grace C. Lee
SSSusanne Schmidt
Susanne Schmidt
KRKelly R. Reveles
Kelly R. Reveles
Christopher Raymond FreiChristopher Raymond Frei
Christopher Raymond Frei
Introduction: Community-acquired bacterial pneumonia (CABP) contributes significantly to mortality and healthcare costs worldwide. The use of guideline-concordant antibiotic therapy for CABP is associated with improved outcomes. Methods: This was a retrospective cohort study of inpatients with CABP due to MRSA or P. aeruginosa in the All of Us database. The proportion of patients on guideline-concordant antibiotics or guideline-discordant antibiotics was compared within groups based upon patient age, sex, self-reported race, ethnicity, marital status, alcohol use, and tobacco use. Guideline concordance was determined using the 2019 IDSA/ATS CABP guidelines. Associations were further analyzed using multivariate logistic regression. Results: A total of 336 patients with CABP due to MRSA (152) or P. aeruginosa (184) were included. Guideline-concordant antibiotic therapy was prescribed to 70% of CABP-MRSA patients and for 57% of CABP-P. aeruginosa patients. Independently predictive factors of guideline-concordant antibiotic prescribing for CABP-P. aeruginosa patients were Non-Hispanic Black (NHB) vs. Non-Hispanic White (NHW) race (odds ratio = 0.30, 95% confidence interval = 0.12 – 0.75). Conclusion: In the All of Us database, the majority of CABP-MRSA and CABP-P. aeruginosa patients were prescribed guideline-concordant antibiotic therapy. Race was independently predictive of guideline-concordant antibiotic therapy for patients with CABP-P. aeruginosa, but not CABP-MRSA. NHB patients were less likely to receive guideline-concordant antibiotic therapy than NHW patients when treated for CABP-P. aeruginosa.

28 October 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Open access
HOHenry Ogbeifun
Henry Ogbeifun
CGCorbyn M Gilmore
Corbyn M Gilmore
ZNZohra I. Nooruddin
Zohra I. Nooruddin
SKSupreet Kaur
Supreet Kaur
CNCynthia L. Nguyen
Cynthia L. Nguyen
Christopher Raymond FreiChristopher Raymond Frei
Christopher Raymond Frei
Introduction: Mantle cell lymphoma (MCL) is a rare subtype (5%) of Non-Hodgkin Lymphoma (NHL), with 5-year survival of about 50%. Bruton Tyrosine Kinase inhibitors (BTKis) may improve health outcomes for patients with relapsed or refractory (R/R) MCL. Study objective: The objective of this study was to compare treatment patterns and healthcare utilization for patients with R/R MCL prescribed their first BTKi therapy using data from the national Veterans Health Administration (VHA). Methods: This was a retrospective cohort study of adult patients (18 + years) prescribed BTKis for MCL in all VHA medical facilities in the United States from 1/1/20 to 12/31/23. Data were statistically analyzed using chi-square, Wilcoxon Rank-Sum test, Kaplan-Meier (KM) curves, multivariable negative binomial regression, and Cox Proportional Hazards regression, and a p-value <0.05. Results: There were 494 patients included. Of those included, 177 received ibrutinib, 189 received acalabrutinib, and 128 received zanubrutinib. More patients on ibrutinib switched to other BTKis (27%) compared to patients on acalabrutinib (10%, p < 0.01) or zanubrutinib (9%, p < 0.01). Median (interquartile range [IQR]) laboratory visits at 12 months were higher for ibrutinib (5, 0–12) than acalabrutinib (1, 0–8, p < 0.01) or zanubrutinib (0, 0–6, p < 0.01). Finally, overall survival (OS) was higher for patients on zanubrutinib than those on ibrutinib (p < 0.01) or acalabrutinib (p < 0.01). Conclusions: Patients prescribed acalabrutinib and zanubrutinib experienced fewer laboratory and hematology/oncology visits at 12 months than patients who received ibrutinib. Patients who received zanubrutinib experienced a survival advantage when compared to those treated with ibrutinib.